Sugi Predict

Sugi Predict / Compounds / SCHEMBL30656162

SCHEMBL30656162

SCHEMBL30656162

Cc1ncsc1COc1ccc2sc(C)c(C(=O)N[C@H](C)C(N)=O)c2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 2/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ EDNRA P25101 1/20 0.34
▸ MAOB P27338 3/20 0.33
▸ MAOA P21397 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ LIMK1 P53667 1/20 0.32
▸ ICAM1 P05362 1/20 0.32
▸ SELE P16581 1/20 0.32
▸ VCAM1 P19320 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656238 1.00 HPGDS (0.35) HPGDSNPC1RAB9AEDNRAMAOB
SCHEMBL30656033 0.89 NPC1 (0.33) NPC1RAB9AEDNRASCN9AL3MBTL1
SCHEMBL30656309 0.89 NPC1 (0.33) NPC1RAB9AEDNRASCN9AL3MBTL1
SCHEMBL30656117 0.85 MEN1 (0.37) EDNRAICAM1SELEL3MBTL1KMT2A
SCHEMBL31350338 0.85 PARP10 (0.39) NPC1RAB9AEDNRAPOLBICAM1
SCHEMBL24485445 0.83 GAA (0.47) POLBL3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL24485410 0.83 GAA (0.47) POLBL3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL29630067 0.83 GAA (0.47) POLBL3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL24485492 0.83 GAA (0.47) POLBL3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL29630088 0.83 GAA (0.47) POLBL3MBTL1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 — — US claimed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 — — EP claimed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 — — WO claimed
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 — — US disclosed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 — — EP disclosed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 HPGDS 854/4885NPC1 518/4885RAB9A 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.